What are biosimilars and how do they impact pharmaceutical companies?

Biosimilars are biological products highly similar to an already approved biological medicine. They are not exact generics but aim to provide similar efficacy and safety. For companies like Amgen Inc., biosimilar competition can erode sales of key blockbuster drugs, creating pressure on revenue and market share, necessitating strategic responses such as pipeline diversification and cost management.

What is meant by a "robust oncology portfolio" and why is it important for a biopharma company?

A "robust oncology portfolio" refers to a strong and diverse collection of cancer treatments. For a company like Amgen Inc., this signifies multiple successful drugs, such as Lumakras, addressing various cancer types. It is crucial for sustained revenue growth, establishing a strong market presence, and reducing reliance on any single product, thereby enhancing long-term stability.

How does the Price-to-Earnings (P/E) ratio help assess a company's valuation?

The P/E ratio is a valuation metric comparing a company's share price to its earnings per share. It indicates how much investors are willing to pay for each pound of a company's earnings. A lower P/E, such as Gilead Sciences Inc.'s 14.19, might suggest an attractive valuation, potentially indicating the stock is undervalued compared to its industry peers, assuming consistent earnings.

What are the implications of "biosimilar competition" for investors?

For investors, biosimilar competition typically implies a threat to the market exclusivity and revenue streams of established blockbuster drugs. Companies facing this, such as Amgen Inc. with products like Enbrel and Prolia, may experience reduced sales and profitability, potentially impacting dividend growth and overall financial performance. This often necessitates a focus on innovation and new product development.

How do "high R&D expenses" affect a company's financial health and future prospects?

High Research and Development (R&D) expenses, as seen with Amgen Inc.'s obesity drug progress, can initially weigh on a company's profit margins and earnings. However, these investments are vital for driving future growth by developing new drugs and expanding the product pipeline. Successful R&D can lead to lucrative new revenue streams, market leadership, and long-term shareholder value.

Why would an "attractive valuation" be considered a positive for a stock?

An attractive valuation, like Gilead Sciences Inc.'s forward P/E of 14.19 trading at a discount, suggests that the company's shares may be undervalued relative to its earnings potential or compared to competitors. This could appeal to investors looking for growth opportunities at a reasonable price, as the stock might have significant room for appreciation if its performance improves or market sentiment shifts.

What might "insider sales" indicate to potential investors?

Insider sales refer to company executives or directors selling their own shares. While there can be various personal reasons for such transactions, significant or widespread insider selling, as observed with Gilead Sciences Inc., might signal that those closest to the company perceive limited near-term upside or have concerns about its future performance. Investors often monitor these actions closely.

How do "regulatory delays" affect a biotechnology company's market position?

Regulatory delays, such as those impacting Amgen Inc.'s novel assets like MariTide, can significantly affect a biotechnology company's market position. They delay the launch of potentially lucrative products, postponing revenue generation and allowing competitors to advance. Such delays increase uncertainty, can erode investor confidence, and impact market share, making pipeline execution a critical factor for success.

What is the significance of a "dominant franchise" within a specific disease area like HIV?

A dominant franchise, such as Gilead Sciences Inc.'s strong position in the HIV market with products like Yeztugo and Descovy, provides a stable and predictable revenue stream. This leadership establishes the company as a key player in that therapeutic area, offering a competitive advantage, supporting further investment in related research, and enhancing overall market stability and recognition.

How should a beginner interpret the information provided on this comparison page?

Beginners should interpret this page as an educational tool to understand various financial and market aspects of companies like Amgen Inc. and Gilead Sciences Inc. It offers general insights and context for comparing two biotechnology firms. Please remember, this content is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. Always conduct your own comprehensive research before making investment decisions.

Amgen vs Gilead Sciences

Explore a detailed comparison between Amgen Inc. and Gilead Sciences Inc., examining their distinct business models, financial performance, and relevant market context. This page provides an accessible overview for those seeking to understand key differences and similarities between these two prominent biotechnology companies. Educational content, not financial advice.

Explore a detailed comparison between Amgen Inc. and Gilead Sciences Inc., examining their distinct business models, financial performance, and relevant market context. This page provides an accessibl...

Comparison Snapshot

Key Financial Metrics

AMGN

Metric

GILD

$197.41B

Market Cap

$179.99B

-9.37%

Potential Profit

-8.58%

Buy

Analyst Rating

Buy

Why It's Moving

AMGN Stock Warning: Why Analysts See -11% Downside Risk

Bernstein downgraded AMGN to Market Perform, citing Repatha's growth at risk from Merck's upcoming oral rival Enlicitide, which could intensify price wars in cholesterol treatments.
Freedom Capital shifted to Hold as shares near fair value, even after raising revenue forecasts based on Amgen's strong low-end 2026 guidance that beat expectations.
Barclays launched coverage with Equal Weight and a below-current-price target, noting ample time before Phase 3 MariTide results, tempering near-term upside from the obesity contender.

Sentiment:

🐻Bearish

GILD Stock Warning: Why Analysts See -9% Downside Risk

Barclays launched coverage with an Equal-Weight rating, aligning with average analyst targets implying over 5% downside and projecting a 4.57% drop in annual revenue to $28.1 billion.
Zacks Consensus shows Q1 EPS estimates dipping 2.4% recently, contributing to a Hold rating amid slower growth outlook for the HIV drugmaker.
Recent dividend boost to $0.82 per share and $7.8B Arcellx buyout for anito-cel expansion offer some uplift, but fail to offset broader profitability concerns.

Sentiment:

🐻Bearish

AMGN Stock Warning: Why Analysts See -11% Downside Risk

Bernstein downgraded AMGN to Market Perform, citing Repatha's growth at risk from Merck's upcoming oral rival Enlicitide, which could intensify price wars in cholesterol treatments.
Freedom Capital shifted to Hold as shares near fair value, even after raising revenue forecasts based on Amgen's strong low-end 2026 guidance that beat expectations.
Barclays launched coverage with Equal Weight and a below-current-price target, noting ample time before Phase 3 MariTide results, tempering near-term upside from the obesity contender.

Sentiment:

🐻Bearish

GILD Stock Warning: Why Analysts See -9% Downside Risk

Barclays launched coverage with an Equal-Weight rating, aligning with average analyst targets implying over 5% downside and projecting a 4.57% drop in annual revenue to $28.1 billion.
Zacks Consensus shows Q1 EPS estimates dipping 2.4% recently, contributing to a Hold rating amid slower growth outlook for the HIV drugmaker.
Recent dividend boost to $0.82 per share and $7.8B Arcellx buyout for anito-cel expansion offer some uplift, but fail to offset broader profitability concerns.

Sentiment:

🐻Bearish

Investment Analysis

Amgen

AMGN

Pros

Amgen maintains a robust oncology portfolio with blockbuster drugs like Lumakras driving consistent revenue growth.
Rare disease franchise, including Tepezza, provides high-margin recurring revenues and shields against generic erosion.
Strong balance sheet supports dividend growth and strategic acquisitions amid pipeline advancements.

Considerations

Biosimilar competition erodes sales of key blockbusters such as Enbrel and Prolia.
High R&D expenses pressure margins despite obesity drug progress in early stages.
Regulatory delays in novel assets like MariTide expose pipeline execution risks.

Gilead Sciences

GILD

Pros

Dominant HIV franchise with Yeztugo launch momentum bolsters market share alongside Descovy's 45% penetration.
Attractive valuation at forward P/E of 14.19 trades at discount to industry peers.
Expanding oncology pipeline nears key regulatory milestones for sustained growth.

Considerations

Upcoming quarterly EPS projected to decline 1.58% year-over-year amid flat revenue.
Recent insider sales signal potential short-term concerns over performance.
Modest consensus price target implies limited near-term upside from current levels.

Related Market Insights

The Biotech Revolution: Why These Medical Pioneers Could Transform Your Portfolio

Explore the biotech revolution driven by CRISPR & regulatory support. Invest in leaders like Amgen, Gilead, Biogen. Discover high-growth medical pioneers.

Aimee Silverwood | Financial Analyst

July 25, 2025

Read Insight

The Cancer Treatment Revolution: Why Multiple Myeloma Breakthroughs Matter

Discover breakthrough multiple myeloma treatments. Invest in companies pioneering bispecific antibodies & CAR-T therapies driving the next cancer revolution. Explore the Neme.

Aimee Silverwood | Financial Analyst

July 25, 2025

Read Insight

AstraZeneca's Breakthrough Could Reshape Hypertension Treatment Forever

Explore the Hypertension Therapy Innovators Neme. AstraZeneca's baxdrostat breakthrough signals a new era in high blood pressure treatment. Invest in leading pharma giants.

Amgen's next earnings date is estimated for April 29-30, 2026, covering the Q1 2026 quarter, based on historical reporting patterns and analyst projections. This follows the most recent Q4 2025 report released on February 3, 2026. Official confirmation from the company is pending, with estimates varying slightly across sources.

Gilead Sciences (GILD) Next Earnings Date

Gilead Sciences' next earnings date is estimated for April 23, 2026, based on historical patterns following the recent Q4 and full-year 2025 results released on February 10, 2026. This report will cover the first quarter of 2026 financial performance. Investors should monitor for an official announcement, as the exact date within the late April window remains unconfirmed.

Amgen (AMGN) Next Earnings Date

Amgen's next earnings date is estimated for April 29-30, 2026, covering the Q1 2026 quarter, based on historical reporting patterns and analyst projections. This follows the most recent Q4 2025 report released on February 3, 2026. Official confirmation from the company is pending, with estimates varying slightly across sources.

Gilead Sciences (GILD) Next Earnings Date

Gilead Sciences' next earnings date is estimated for April 23, 2026, based on historical patterns following the recent Q4 and full-year 2025 results released on February 10, 2026. This report will cover the first quarter of 2026 financial performance. Investors should monitor for an official announcement, as the exact date within the late April window remains unconfirmed.

Which Baskets Do They Appear In?

Hypertension Therapy Innovators

This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.

Published: July 15, 2025

Explore Basket

Next-Gen Multiple Myeloma Treatments

Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.

Published: July 3, 2025

Explore Basket

Top Biotech Stocks

Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.

Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.

Published: May 29, 2025

Explore Basket

Amgen vs Gilead Sciences

Comparison Snapshot

Why It's Moving

AMGN Stock Warning: Why Analysts See -11% Downside Risk

GILD Stock Warning: Why Analysts See -9% Downside Risk

AMGN Stock Warning: Why Analysts See -11% Downside Risk

GILD Stock Warning: Why Analysts See -9% Downside Risk

Investment Analysis

Amgen

Pros

Considerations

Gilead Sciences

Pros

Considerations

Related Market Insights

The Biotech Revolution: Why These Medical Pioneers Could Transform Your Portfolio

The Cancer Treatment Revolution: Why Multiple Myeloma Breakthroughs Matter

AstraZeneca's Breakthrough Could Reshape Hypertension Treatment Forever

Related Market Insights

The Biotech Revolution: Why These Medical Pioneers Could Transform Your Portfolio

The Cancer Treatment Revolution: Why Multiple Myeloma Breakthroughs Matter

AstraZeneca's Breakthrough Could Reshape Hypertension Treatment Forever

About Amgen and Gilead Sciences

Amgen (AMGN) Next Earnings Date

Gilead Sciences (GILD) Next Earnings Date

Amgen (AMGN) Next Earnings Date

Gilead Sciences (GILD) Next Earnings Date

Which Baskets Do They Appear In?

Hypertension Therapy Innovators

Next-Gen Multiple Myeloma Treatments

Top Biotech Stocks

Which Baskets Do They Appear In?

Hypertension Therapy Innovators

Next-Gen Multiple Myeloma Treatments

Top Biotech Stocks

Buy AMGN or GILD in Nemo

Zero Commission

Trusted & Regulated

6% Interest on Cash

Frequently asked questions

What are biosimilars and how do they impact pharmaceutical companies?

What is meant by a "robust oncology portfolio" and why is it important for a biopharma company?

How does the Price-to-Earnings (P/E) ratio help assess a company's valuation?

What are the implications of "biosimilar competition" for investors?

How do "high R&D expenses" affect a company's financial health and future prospects?

Why would an "attractive valuation" be considered a positive for a stock?

What might "insider sales" indicate to potential investors?

How do "regulatory delays" affect a biotechnology company's market position?

What is the significance of a "dominant franchise" within a specific disease area like HIV?

How should a beginner interpret the information provided on this comparison page?

Comparison Snapshot

About Amgen and Gilead Sciences